Mobilization and harvesting of peripheral blood stem cells

Randomized evaluations of different doses of filgrastim

C. H. Weaver, R. Birch, F. A. Greco, Lee Schwartzberg, B. Mcaneny, M. Moore, D. Oviatt, J. Redmond, C. George, T. Alberico, P. Johnson, C. D. Buckner

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

The effects of different doses of filgrastim on yields of CD34+ peripheral blood stem cells were evaluated in patients with breast cancer. 55 were randomized to receive filgrastim 10, 20, 30 or 40 μg/kg/d with more CD34+ cells/kg/apheresis harvested after the three highest dose levels. 35 additional patients were randomized to receive 10 or 30 μg/kg. The median number of CD34+ cells collected after 10 μg/kg (n= 31) was 0.7x 106/kg/apheresis (range 0.1-4.4) as compared to 1.2 (range 0.1-6.8) after 30μg/kg (n=32) (P=0.04). Among patients randomized to 10 v 30μg/kg, more (50%) achieved ≤ 5.0x106 CD34+ cells/kg and less aphereses were required to achieve ≤ 2.5 x 106 CD34+ cells/kg after the higher dose (P = 0.04). In multivariate analyses, patients receiving 10μg/kg (n=31) had lower yields of CD34+ cells (P= 0.026) and had a 3.3-fold increase in the probability of not achieving ≤ 5.0 x 106 CD34+ cells/kg as compared to patients receiving 20- 40μg/kg (n=59). Patients who had received radiation had a 2·9-fold probability of not achieving ≤2·5x 106 CD34+ cells/kg. These data suggest that, in patients with good marrow reserves, doses of filgrastim > 10μg/kg/d mobilized more CD34+ cells and may be useful when high numbers of CD34+ cells are desired.

Original languageEnglish (US)
Pages (from-to)338-347
Number of pages10
JournalBritish Journal of Haematology
Volume100
Issue number2
DOIs
StatePublished - Apr 2 1998

Fingerprint

Blood Component Removal
Cell Count
Peripheral Blood Stem Cells
Filgrastim
Multivariate Analysis
Bone Marrow
Radiation
Breast Neoplasms

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Mobilization and harvesting of peripheral blood stem cells : Randomized evaluations of different doses of filgrastim. / Weaver, C. H.; Birch, R.; Greco, F. A.; Schwartzberg, Lee; Mcaneny, B.; Moore, M.; Oviatt, D.; Redmond, J.; George, C.; Alberico, T.; Johnson, P.; Buckner, C. D.

In: British Journal of Haematology, Vol. 100, No. 2, 02.04.1998, p. 338-347.

Research output: Contribution to journalArticle

Weaver, CH, Birch, R, Greco, FA, Schwartzberg, L, Mcaneny, B, Moore, M, Oviatt, D, Redmond, J, George, C, Alberico, T, Johnson, P & Buckner, CD 1998, 'Mobilization and harvesting of peripheral blood stem cells: Randomized evaluations of different doses of filgrastim', British Journal of Haematology, vol. 100, no. 2, pp. 338-347. https://doi.org/10.1046/j.1365-2141.1998.00573.x
Weaver, C. H. ; Birch, R. ; Greco, F. A. ; Schwartzberg, Lee ; Mcaneny, B. ; Moore, M. ; Oviatt, D. ; Redmond, J. ; George, C. ; Alberico, T. ; Johnson, P. ; Buckner, C. D. / Mobilization and harvesting of peripheral blood stem cells : Randomized evaluations of different doses of filgrastim. In: British Journal of Haematology. 1998 ; Vol. 100, No. 2. pp. 338-347.
@article{a09fe2cd1f1146099187061d05232e6b,
title = "Mobilization and harvesting of peripheral blood stem cells: Randomized evaluations of different doses of filgrastim",
abstract = "The effects of different doses of filgrastim on yields of CD34+ peripheral blood stem cells were evaluated in patients with breast cancer. 55 were randomized to receive filgrastim 10, 20, 30 or 40 μg/kg/d with more CD34+ cells/kg/apheresis harvested after the three highest dose levels. 35 additional patients were randomized to receive 10 or 30 μg/kg. The median number of CD34+ cells collected after 10 μg/kg (n= 31) was 0.7x 106/kg/apheresis (range 0.1-4.4) as compared to 1.2 (range 0.1-6.8) after 30μg/kg (n=32) (P=0.04). Among patients randomized to 10 v 30μg/kg, more (50{\%}) achieved ≤ 5.0x106 CD34+ cells/kg and less aphereses were required to achieve ≤ 2.5 x 106 CD34+ cells/kg after the higher dose (P = 0.04). In multivariate analyses, patients receiving 10μg/kg (n=31) had lower yields of CD34+ cells (P= 0.026) and had a 3.3-fold increase in the probability of not achieving ≤ 5.0 x 106 CD34+ cells/kg as compared to patients receiving 20- 40μg/kg (n=59). Patients who had received radiation had a 2·9-fold probability of not achieving ≤2·5x 106 CD34+ cells/kg. These data suggest that, in patients with good marrow reserves, doses of filgrastim > 10μg/kg/d mobilized more CD34+ cells and may be useful when high numbers of CD34+ cells are desired.",
author = "Weaver, {C. H.} and R. Birch and Greco, {F. A.} and Lee Schwartzberg and B. Mcaneny and M. Moore and D. Oviatt and J. Redmond and C. George and T. Alberico and P. Johnson and Buckner, {C. D.}",
year = "1998",
month = "4",
day = "2",
doi = "10.1046/j.1365-2141.1998.00573.x",
language = "English (US)",
volume = "100",
pages = "338--347",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Mobilization and harvesting of peripheral blood stem cells

T2 - Randomized evaluations of different doses of filgrastim

AU - Weaver, C. H.

AU - Birch, R.

AU - Greco, F. A.

AU - Schwartzberg, Lee

AU - Mcaneny, B.

AU - Moore, M.

AU - Oviatt, D.

AU - Redmond, J.

AU - George, C.

AU - Alberico, T.

AU - Johnson, P.

AU - Buckner, C. D.

PY - 1998/4/2

Y1 - 1998/4/2

N2 - The effects of different doses of filgrastim on yields of CD34+ peripheral blood stem cells were evaluated in patients with breast cancer. 55 were randomized to receive filgrastim 10, 20, 30 or 40 μg/kg/d with more CD34+ cells/kg/apheresis harvested after the three highest dose levels. 35 additional patients were randomized to receive 10 or 30 μg/kg. The median number of CD34+ cells collected after 10 μg/kg (n= 31) was 0.7x 106/kg/apheresis (range 0.1-4.4) as compared to 1.2 (range 0.1-6.8) after 30μg/kg (n=32) (P=0.04). Among patients randomized to 10 v 30μg/kg, more (50%) achieved ≤ 5.0x106 CD34+ cells/kg and less aphereses were required to achieve ≤ 2.5 x 106 CD34+ cells/kg after the higher dose (P = 0.04). In multivariate analyses, patients receiving 10μg/kg (n=31) had lower yields of CD34+ cells (P= 0.026) and had a 3.3-fold increase in the probability of not achieving ≤ 5.0 x 106 CD34+ cells/kg as compared to patients receiving 20- 40μg/kg (n=59). Patients who had received radiation had a 2·9-fold probability of not achieving ≤2·5x 106 CD34+ cells/kg. These data suggest that, in patients with good marrow reserves, doses of filgrastim > 10μg/kg/d mobilized more CD34+ cells and may be useful when high numbers of CD34+ cells are desired.

AB - The effects of different doses of filgrastim on yields of CD34+ peripheral blood stem cells were evaluated in patients with breast cancer. 55 were randomized to receive filgrastim 10, 20, 30 or 40 μg/kg/d with more CD34+ cells/kg/apheresis harvested after the three highest dose levels. 35 additional patients were randomized to receive 10 or 30 μg/kg. The median number of CD34+ cells collected after 10 μg/kg (n= 31) was 0.7x 106/kg/apheresis (range 0.1-4.4) as compared to 1.2 (range 0.1-6.8) after 30μg/kg (n=32) (P=0.04). Among patients randomized to 10 v 30μg/kg, more (50%) achieved ≤ 5.0x106 CD34+ cells/kg and less aphereses were required to achieve ≤ 2.5 x 106 CD34+ cells/kg after the higher dose (P = 0.04). In multivariate analyses, patients receiving 10μg/kg (n=31) had lower yields of CD34+ cells (P= 0.026) and had a 3.3-fold increase in the probability of not achieving ≤ 5.0 x 106 CD34+ cells/kg as compared to patients receiving 20- 40μg/kg (n=59). Patients who had received radiation had a 2·9-fold probability of not achieving ≤2·5x 106 CD34+ cells/kg. These data suggest that, in patients with good marrow reserves, doses of filgrastim > 10μg/kg/d mobilized more CD34+ cells and may be useful when high numbers of CD34+ cells are desired.

UR - http://www.scopus.com/inward/record.url?scp=6844250966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=6844250966&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2141.1998.00573.x

DO - 10.1046/j.1365-2141.1998.00573.x

M3 - Article

VL - 100

SP - 338

EP - 347

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 2

ER -